Fritextsökning
Artiklar per år
Innehållstyper
-
“You discover one thing – and then 10 new questions arise”
COVID-19, diabetes, heart disease, and the impact of dog ownership on humans are just some of multitasker Tove Fall’s areas of research. However, her current focus is on her next field: the role of gut flora in human health.
-
Novo Nordisk buys drug candidate in billion dollar deal
The Danish pharmaceutical giant Novo Nordisk have made an agreement with KBP Biosciences to aqcuire the hypertension drug ocedurenone for up to 1.3 billion dollars, which corresponds to approximately 14 billion Swedish kronor.
-
Högteknologiska bolag allt mer intresserade av hälsa
Under många år har techföretag intresserat sig för hälso- och sjukvården och det intresset ser ut att öka. ”Det är inget plötsligt trendbrott, det handlar mer om att de flyttar fram positionerna”, säger Anna Lefevre Skjöldebrand, vd för Swedish Medtech.
-
The physician at the tech giant: “Observations in the emergency room made my mind up”
When Nasim Farrokhnia was in third grade at school in Tehran, the capital of Iran, her father gave her a book about Marie Curie, which soon became her favourite book. Perhaps her interest in science was born there and then, as science and new technology have since been a constant feature of her working life. Today, she is a Healthcare Manager in Microsoft’s Western Europe team.
-
Study names with an attitude – more important than you might think
Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.
-
Rickard Sandberg on this year’s Nobel Prize in Medicine: ”A key discovery”
The discovery that paved the way for the development of todays mRNA vaccines is the basis for this year’s Nobel Prize in Physiology or Medicine.
-
The first drugs to slow down Alzheimer’s – but what does it mean for patients?
New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the right patients be found in time, and will the healthcare system’s resources be sufficient? Life Science Sweden has spoken to Swedish researchers in Alzheimer’s who voice cautious hope but also see further challenges.
-
Marie Gårdmark: ”The situation is not satisfactory”
”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration of new products in rare diseases. But will it also work to increase access for all EU patients?” writes Marie Gårdmark in a column.
-
Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”
With mixed emotions, Charlotta Gummeson will leave her position as CEO of Sahlgrenska Science Park in October. “It feels sad and exciting at the same time. I’ve been in the thick of things and part of the development for so long now, but I’m also looking forward and thinking about all the new things that there will be in a freer role,” she says to Life Science Sweden
-
Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”
It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless different assignments later, Per Alfredsson, born and raised in Södertälje, is CEO of Astra Zeneca Sweden, which employs 7800 people in Södertälje, Stockholm and Gothenburg. “It was a very special feeling to be in charge of the entire organisation,” he says in an interview about his career and potential future blockbusters.
-
Studienamn med attityd – viktigare än man kan tro
Ironman, T-rex, Star-trec. Popcorn, Proper, Scout. Nej, det handlar varken om fantasyfilmer eller hundnamn. Utan om benämningar på pågående cancerstudier i Sverige.
-
Pfizer’s Paxlovid is being tested against post-COVID in a major Swedish study
In a new study conducted at the Karolinska University Hospital, Pfizer’s COVID drug, Paxlovid, is now being tested in patients with post-COVID. The study is one of the most extensive studies in the world currently being conducted for a drug for post-COVID.
-
19 medicines in Sweden are under investigation in a major EMA inquiry
19 medicines marketed in Sweden are affected by an ongoing extensive European investigation into suspected fraud at an Indian contract research organisation. Among them are medicines for HIV, epilepsy, cancer and Parkinson’s, which may be withdrawn unless new evidence can be provided that they are up to standard.
-
The Swedish government is to increase its investment in cancer care
The Swedish government wants to invest more in cancer and paediatric cancer care and proposes to allocate SEK 500 million per year for this purpose in the coming years.
-
From the sea of Åland to a self-test for lithium
Four years ago, a meeting on the sea of Åland resulted in the development of a self-test for lithium levels in the blood. The hopes are that the test will be available for individuals with bipolar disorder in the future.
-
Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients
In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.
-
Heidi Stensmyren is eager for new challenges in the biotech industry
Heidi Stensmyren has served as President of the Swedish Medical Association, held a managerial position at Karolinska University Hospital and is now Medical Director at a biotech company. “I’m curious and like to have influence, so I’ve often chosen management roles,” she says.
-
Here are the pharmaceutical companies best prepared for AI
How well prepared are pharmaceutical companies in the field of artificial intelligence? That is what a new analysis has tried to evaluate.
-
Life Science Sweden heads to the Oresund region! ‒ Hello there Michael Linnell
Life Science Sweden’s The Future of Swedish Danish Life Science and New Updates in Drug Formulation & Bioavailability meetings are coming up soon. We asked Michael Linnell, project manager for Life Science Sweden’s event portfolio, a few short questions.
-
Bioarctic granted Japanese patent for Parkinson’s disease candidate
Bioarctic has been granted a Japanese patent for its antibodies targeting Parkinson’s disease.
-
“Unfortunately, we are not strong when it comes to conducting clinical trials”
The number of company-initiated clinical trials conducted in Sweden has been declining in recent years. In mid-March, a government inquiry was presented that aimed to find answers and solutions to this downward trend. One of the proposals was a stable, sustainable and funded model for collaboration.
-
Small robots to deliver pharmaceuticals to the body
Robots that can operate inside the body and a platform that combines ultrasound with AI. These are a couple of the technologies that have qualified for a list that aims to promote sustainable entrepreneurship.
-
Double up for Korbinian Löbmann
This year, Korbinian Löbmann will moderate the New Updates in Drug Formulation & Bioavailability meeting in Copenhagen for the fifth time. Furthermore, he will also moderate The Future of Swedish & Danish Life Science congress in Lund for the first time.
-
CROs in drug development: "We use our expertise to speed up the process
Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that it will change,” says Helena Lüning of the industry organisation ASCRO.